Evidence Hub

Data from: Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression

Juliana Mira Hernandez, Logan Bailey, Victoria Salemme, Christopher Y. Ko, Erin Shen, Megan Ngim, Duong Hoang, Melissa Corea et al.

DRYAD, 2026

Abstract

This dataset contains the source data supporting the article entitled Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression. The dataset supports key findings on the effects of chronic in vivo empagliflozin treatment on excitation-contraction coupling (ECC), electrophysiology, gene transcription, and protein expression in a translational two-hit heart failure with preserved ejection fraction (HFpEF) mouse model that combines the obese-diabetic leptin receptor deficient db/db mice with chronic aldosterone infusion (db/db+Aldo). Morphometry, echocardiography, cardiomyocyte electrophysiology (action potentials and ionic currents), fluorescent Ca imaging, whole-heart RNA sequencing, and immunoblot data are included in separate Excel sheets with individual cell data and group statistics. The dataset is structured to follow the sequence of data presented in the Figures in the article and to ease the navigation between the uploaded data files.

How strong is the evidence?

Evidence Hub reads this as a dataset, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free